A molecular intelligence platform company.

Our Mission

01 / 04

Measure disease at its biological source.

For decades, diabetes diagnostics have relied on indirect markers — glucose, HbA1c, insulin, C-peptide — that measure the downstream consequences of disease after substantial damage has already occurred. Kihealth Labs was founded on the conviction that disease should be measured at its source: the active molecular biology inside the cells that are failing.

Scientific Origin

02 / 04

Born from pioneering Type 1 diabetes research at Yale.

Kihealth was founded on scientific discoveries originating from research conducted at Yale University by Dr. Kevin Herold, one of the world's leading Type 1 diabetes investigators and a key contributor to the development of teplizumab — the first FDA-approved therapy shown to delay the onset of Stage 3 Type 1 diabetes. Our first technology detects active beta-cell death through cell-free DNA biomarkers released from injured pancreatic beta cells, providing a direct molecular signal of beta-cell injury years before metabolic decompensation.

InterceptIQ™ Platform

03 / 04

From a single discovery to a molecular intelligence platform.

We have extended that scientific foundation into InterceptIQ™ — a proprietary disease interception liquid biopsy platform that transforms a simple blood sample into actionable clinical intelligence through cell-free DNA analysis, epigenetic characterization, and AI-driven molecular intelligence. One substrate. Many programs. A common molecular grammar across diabetes, oncology, and neurodegenerative disease.

Disease Interception Vision

04 / 04

From reactive disease management to proactive interception.

Today's standard of care waits for a clinical event — an A1c crossing threshold, a tumor visible on imaging, a cognitive decline noted by family. Disease interception flips that model: identify cellular injury, dysfunction, and degeneration during the molecular window when outcomes can still be changed, and use that signal for earlier intervention, patient stratification, therapeutic monitoring, and precision medicine.